Clinical trials: Oral Chemotherapy
Acute Myeloid Leukemia
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow (the spongy tissue inside the bones) that affects white…
- Trial name
- REVIVAL (NCT07581002)
- Testing
- Pivekimab Sunirine, Venetoclax, Azacitidine
- Where
- 38 sites in United States, Austria and 5 more
- Volunteers
- 660 people
- Sponsor
- AbbVie
Non-small Cell Lung Cancer
A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen
This study will compare PF-00299804 given orally on continuous schedule to the approved drug, erlotinib, in patients whose non-small cell lung cancer has progressed after chemotherapy; patients will be randomized to receive one…
- Trial name
- NCT00769067
- Testing
- Erlotinib, PF-00299804
- Where
- 59 sites in United States, Australia and 10 more
- Volunteers
- 188 people
- Sponsor
- Pfizer
Carcinoma, Non-Small Cell Lung
PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients
The main purpose of this study is to evaluate the overall safety and maximum dose of CI 1033 in combination with paclitaxel and carboplatin in patients with NSCLC.
- Trial name
- NCT00174356
- Testing
- CI 1033, PACLITAXEL, CARBOPLATIN
- Where
- 7 sites in United States, Canada
- Volunteers
- 39 people
- Sponsor
- Pfizer
Chemotherapy Induced Nausea and Vomiting
Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting
The primary purpose of the study is to determine the efficacy of oral dronabinol versus standard ondansetron antiemetic therapy in preventing delayed-onset chemotherapy-induced nausea and vomiting (CINV) or retching by measuring…
- Trial name
- NCT00642512
- Testing
- dronabinol, ondansetron, dronabinol/ondansetron
- Where
- 43 sites in United States
- Volunteers
- 64 people
- Sponsor
- Solvay Pharmaceuticals
Advanced Nonhematologic Malignancies
A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies
The purpose of this study was to evaluate the safety and to determine dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), and dosing schedules of oral TAK-228+TAK-117.
- Trial name
- NCT01899053
- Testing
- TAK-228, TAK-117
- Where
- 5 sites in United States, Spain and 1 more
- Volunteers
- 101 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Memory Impairment, Alzheimer's Disease
Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults
The purpose of this study is to determine whether scopolamine-induced cognitive impairment is attenuated by the administration of roflumilast in combination with donepezil.
- Trial name
- NCT02051335
- Testing
- Roflumilast, Donepezil, Scopolamine
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Renal Impairment, Hepatic Impairment
Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment
The purpose of this study is to examine the effects of renal and hepatic impairment on TAK-272 pharmacokinetics with a single oral administration of TAK-272 in participants with renal or hepatic impairment.
- Trial name
- NCT02367872
- Testing
- TAK-272
- Where
- 4 sites in Japan
- Volunteers
- 48 people
- Sponsor
- Takeda
Metastatic Breast Cancer
BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer
This is a prospective, multi-center, open-label, single arm, phase II study with a 2-stage design and Bayesian interim monitoring to investigate the safety and efficacy of BEZ235 in patients with progressive metastatic HR+ HER2…
- Trial name
- NCT01288092
- Testing
- BEZ235
- Sponsor
- Novartis Pharmaceuticals
Mucositis
Phase 2a Study to Evaluate Suppression of 5-Fluorouracil -Induced Mucositis by TK112690
Patients expected to receive a 500 mg/m2 of Leucovorin by iv \& 500 mg/m2 of Fluorouracil (5FU) by iv bolus for their Colorectal Cancer.
- Trial name
- NCT05669521
- Testing
- TK-112690
- Where
- 5 sites in India
- Volunteers
- 24 people
- Sponsor
- Tosk, Inc.
Thrombocytopaenia
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
The present study is a randomized, blinded, placebo-controlled, two-Phase, sequential cohort, dose finding study to assess the safety and efficacy of eltrombopag in patients with solid tumors receiving gemcitabine monotherapy or…
- Trial name
- NCT01147809
- Testing
- Eltrombopag olamine
- Where
- 86 sites in United States, Belgium and 11 more
- Volunteers
- 130 people
- Sponsor
- GlaxoSmithKline
Schizophrenia
A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia
The purpose of this study is to determine whether luvadaxistat is superior to placebo in improving cerebellar function as measured with the average percentage of conditioned responses during the eyeblink conditioning (EBC) test.
- Trial name
- NCT03359785
- Testing
- Luvadaxistat
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Neurocrine Biosciences
Oral Mucositis
Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
The purpose of this study is to assess the safety and tolerability of AG013 (genetically modified L. lactis bacteria engineered to secrete human Trefoil Factor 1), and to explore the ability of AG013 to attenuate the course and…
- Trial name
- NCT00938080
- Testing
- AG013
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- ActoGeniX N.V.
Breast Neoplasms
An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer
The purpose of this trial is to evaluate the efficacy, safety and pharmacokinetics of BIBW 2992, a dual, irreversible EGFR- and HER2-inhibitor, in two cohorts of patients with HER2-negative breast cancer after failure of no more…
- Trial name
- NCT00425854
- Testing
- BIBW 2992
- Where
- 14 sites in Belgium, Germany
- Volunteers
- 50 people
- Sponsor
- Boehringer Ingelheim
Gout
Food Effect Study of Febuxostat XR in Healthy Participants
The purpose of this study is to assess the effect of food on the bioavailability of febuxostat after a single oral dose of 80 mg febuxostat XR and to evaluate the pharmacokinetics (PK) of febuxostat after single oral doses of 40…
- Trial name
- NCT02374164
- Testing
- Febuxostat XR
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Takeda
Acute Myeloid Leukemia
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
This is a study to evaluate PF-04449913 (an inhibitor of the Hedgehog pathway) in Acute Myeloid Leukemia and high-risk Myelodysplastic Syndrome in combination with standard agents used to treat these diseases.
- Trial name
- NCT01546038
- Testing
- PF-04449913, Low dose ARA-C (LDAC), Decitabine
- Where
- 81 sites in United States, Canada and 4 more
- Volunteers
- 255 people
- Sponsor
- Pfizer
Nausea and Vomiting, Chemotherapy-Induced
Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]
This is a two period study of healthy adult subjects to characterize the effect of the dosing of ketoconazole on the the way the body reacts to a dose of GW679769, and to assess the safety profile of oral casopitant with and…
- Trial name
- NCT00404378
- Testing
- ketoconazole, casopitant 100 mg, Casopitant 50 mg
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cancer
Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists
This study will examine the efficacy and safety of lapatinib in patients with ErbB2 positive ovarian, gastric/esophageal adenocarcinoma, uterine serous papillary, or bladder cancers.
- Trial name
- NCT00447226
- Where
- 20 sites in United States
- Volunteers
- 32 people
- Sponsor
- GlaxoSmithKline
NSCLC
Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer
This is a multicenter, open-label, randomised, phase III study of 2 cycles of oral vinorelbine in combination with cisplatin concurrently with radiotherapy randomised to either two more cycles of consolidation therapy with oral…
- Trial name
- NCT00683514
- Testing
- Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)
- Where
- Germany
- Volunteers
- 201 people
- Sponsor
- Pierre Fabre Medicament
Uterine Fibroids
A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids
The purpose of this study is to evaluate the efficacy and safety of Relugolix (TAK-385) in patients having pain symptoms associated with uterine fibroids.
- Trial name
- NCT02655224
- Testing
- Relugolix
- Where
- 11 sites in Japan
- Volunteers
- 65 people
- Sponsor
- Takeda
Healthy Participants
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants
The purpose of this study is to assess the safety and tolerability of TAK-994 following single and multiple oral doses in healthy non-Japanese and Japanese adult participants and healthy elderly participants.
- Trial name
- NCT03933488
- Testing
- TAK-994
- Where
- 2 sites in United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Takeda